Merus focuses on the discovery and development of bispecific antibodies and Oligoclonics™ product candidates against targets in oncology, chronic inflammation and infectious diseases.
Lead candidates are selected for synergistic effects in in vitro assays and in vivo models of human disease. After production of bispecific antibodies and Oligoclonics™ antibody formats in a single, clonal cell, superiority over single monoclonal antibody therapies is established.
Current targets include combinations of surface expressed molecules on tumor cells, cytokines and viruses. Merus plans to take the most promising bispecific antibodies and Oligoclonics™ product candidates into pre-clinical development and clinical testing to provide proof of superior clinical efficacy.
Merus Pipeline
